Provider Networks
Expert articles and analysis related to provider networks.
AI Summary — Last 30 Days
CMS is moving provider-network strategy toward tech-enabled, condition-specific value-based care: the voluntary ACCESS model has accepted roughly 150 participants and will tie Medicare payments to measurable outcomes for chronic conditions including obesity, diabetes, musculoskeletal pain, and depression, positioning digital health vendors, ACO enablement firms, and tech-enabled plans as network-extenders rather than peripheral partners (ACCESS participants). For ACOs and payers, the strategic tension is whether these lean, voluntary models can generate scalable savings and better longitudinal management without fragmenting accountability—especially as MSSP reform efforts continue to focus on expanding ACO participation and savings potential (MSSP participation and savings.
Related Articles
New Bill Seeks to Lower Out-of-Pocket Drug Costs
New Bill Seeks to Lower Out-of-Pocket Drug Costs MedCity News
Will CMS' new BALANCE model make GLP-1s more affordable?
Will CMS' new BALANCE model make GLP-1s more affordable? Advisory Board
Two visions for value – Why GCEA and HEMA clash on drug pricing
That is the title of my latest Perspectives from the Healthcare Economist article published in The Evidence Base this week. Here is the teaser: In this guest column, healthcare economist Jason Shafrin...
change its pharmacy care model
From newsletter: The LI Daily: Ascendiun CEO Paul Markovich wants the industry to back a policy reform movement focused on affordability, tech innovation Ascendiun CEO Paul Markovich wants the indus...
Trends in Manufacturer Coupons for Biologics: Decline in Use Despite Higher Per-Claim Value
Premier Responds to RFI on Potential 340B Rebate Model Pilot Program
Premier raised concerns that a rebate based approach to the 340B drug discount program would undermine the program and create significant risk for hospitals.
Standing up to Rising Prescription Drug Costs Increases Access to Breakthrough Medications
For millions of Americans, accessing the medications they need at prices they can afford has gotten increasingly difficult.
‘Most Favored Nation’ Drug Pricing Is An Idea Whose Time Has Come
‘Most Favored Nation’ Drug Pricing Is An Idea Whose Time Has Come Health Affairs
Rising Specialty Drug Costs and Co-Pay Models Raise Access Concerns: Patty Taddei-Allen, PharmD, MBA
The AbbVie 340B Lawsuit Signals a Shift from Access to Definition
A recent federal lawsuit filed by AbbVie may prove to be one of the most consequential developments in the evolution of the 340B Drug Pricing Program. While much of the past decade has focused on acce...